DOWNSIDE: GSK needs to hope a clinical study, which found that Avandia reduced by 62% the chance at-risk patients would go on to develop Type 2 diabetes, is correct. That's because both Novartis and Merck have new treatments on the horizon that some analysts believe will undermine older meds such as Avandia. But if GSK can market the fact that Avandia slows the progression of diabetes as well as treats existing diabetics, it may have a whole new life.
AD BUDGET: $2.19 billion
* Havas' Arnold, Euro RSCG and MPG, N.Y.
* Interpublic's FCB HealthCare & ProHealth, McCann HumanCare; Torre Lazur McCann
* Omnicom's BBDO, N.Y.
* Publicis' Publicis Mid-America, Dallas; Saatchi & Saatchi, N.Y.
* WPP's CommonHealth, Grey, MediaCom, Wing Latino, Mediaedge:cia